Article Text
Statistics from Altmetric.com
QUESTION: Is an intranasal, trivalent, live, attenuated influenza virus (LAIV) vaccine effective and safe for reducing febrile illness in healthy, working adults?
Design
Randomised (allocation not concealed*), blinded (participants and study personnel),* placebo controlled trial with follow up during site specific 7 week peak outbreak periods.
Setting
13 sites in the continental United States.
Participants
4561 people (mean age 38 y, 55% women) who were 18 to 64 years of age, worked ≥30 h/wk outside of the home, and had health insurance. Exclusion criteria included hypersensitivity to eggs, indication for or previous receipt of the inactivated vaccine, and pregnancy or unprotected risk for pregnancy in the previous 3 months. Follow up was 93%.
Intervention
From September 18 to November 15, 1997, 3041 participants received the LAIV vaccine …
Footnotes
-
Source of funding: Aviron.
-
For correspondence: Dr K L Nichol, Medicine Service (111), Veterans Affairs Medical Center, 1 Veterans Drive, Minneapolis, MN 55417, USA. Fax +1 612 727 5659.